34118929|t|Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.
34118929|a|BACKGROUND: An increasing number of studies evidences that amyotrophic lateral sclerosis (ALS) is characterized by extensive alterations in different cell types and in different regions besides the CNS. We previously reported the upregulation in ALS models of a gene called fibroblast-specific protein-1 or S100A4, recognized as a pro-inflammatory and profibrotic factor. Since inflammation and fibrosis are often mutual-sustaining events that contribute to establish a hostile environment for organ functions, the comprehension of the elements responsible for these interconnected pathways is crucial to disclose novel aspects involved in ALS pathology. METHODS: Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide. Mice overexpressing human FUS were adopted to assess the effects of niclosamide in vivo on ALS pathology. RESULTS: We demonstrated that S100A4 underlies impaired autophagy and a profibrotic phenotype, which characterize ALS fibroblasts. Indeed, its inhibition reduces inflammatory, autophagic, and profibrotic pathways in ALS fibroblasts, and interferes with different markers known as pathogenic in the disease, such as mTOR, SQSTM1/p62, STAT3, alpha-SMA, and NF-kappaB. Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, alpha-SMA, and PDGFRbeta in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis. CONCLUSION: Our findings show that S100A4 has a role in ALS-related mechanisms, and that drugs such as niclosamide which are able to target inflammatory and fibrotic pathways could represent promising pharmacological tools for ALS.
34118929	10	16	S100A4	Gene	6275
34118929	22	33	niclosamide	Chemical	MESH:D009534
34118929	45	57	inflammatory	Disease	MESH:D007249
34118929	96	125	amyotrophic lateral sclerosis	Disease	MESH:D000690
34118929	186	215	amyotrophic lateral sclerosis	Disease	MESH:D000690
34118929	217	220	ALS	Disease	MESH:D000690
34118929	373	376	ALS	Disease	MESH:D000690
34118929	401	430	fibroblast-specific protein-1	Gene	6275
34118929	434	440	S100A4	Gene	6275
34118929	462	474	inflammatory	Disease	MESH:D007249
34118929	505	517	inflammation	Disease	MESH:D007249
34118929	522	530	fibrosis	Disease	MESH:D005355
34118929	767	770	ALS	Disease	MESH:D000690
34118929	834	837	ALS	Disease	MESH:D000690
34118929	838	846	patients	Species	9606
34118929	861	868	C9orf72	Gene	203228
34118929	905	908	ALS	Disease	MESH:D000690
34118929	909	917	patients	Species	9606
34118929	945	948	ALS	Disease	MESH:D000690
34118929	987	993	S100A4	Gene	6275
34118929	1013	1019	S100A4	Gene	6275
34118929	1046	1057	niclosamide	Chemical	MESH:D009534
34118929	1059	1063	Mice	Species	10090
34118929	1079	1084	human	Species	9606
34118929	1085	1088	FUS	Gene	2521
34118929	1127	1138	niclosamide	Chemical	MESH:D009534
34118929	1150	1153	ALS	Disease	MESH:D000690
34118929	1195	1201	S100A4	Gene	6275
34118929	1279	1282	ALS	Disease	MESH:D000690
34118929	1327	1339	inflammatory	Disease	MESH:D007249
34118929	1381	1384	ALS	Disease	MESH:D000690
34118929	1480	1484	mTOR	Gene	56717
34118929	1486	1492	SQSTM1	Gene	18412
34118929	1493	1496	p62	Gene	23636
34118929	1498	1503	STAT3	Gene	6774
34118929	1505	1514	alpha-SMA	Gene	58
34118929	1520	1530	NF-kappaB.	Gene	18033
34118929	1544	1555	niclosamide	Chemical	MESH:D009534
34118929	1577	1580	ALS	Disease	MESH:D000690
34118929	1581	1584	FUS	Gene	2521
34118929	1585	1589	mice	Species	10090
34118929	1616	1622	S100A4	Gene	20198
34118929	1624	1633	alpha-SMA	Gene	11475
34118929	1639	1648	PDGFRbeta	Gene	18596
34118929	1680	1687	gliosis	Disease	MESH:D005911
34118929	1745	1762	axonal impairment	Disease	MESH:D001480
34118929	1798	1812	muscle atrophy	Disease	MESH:D009133
34118929	1860	1868	fibrosis	Disease	MESH:D005355
34118929	1905	1911	S100A4	Gene	6275
34118929	1926	1929	ALS	Disease	MESH:D000690
34118929	1973	1984	niclosamide	Chemical	MESH:D009534
34118929	2010	2022	inflammatory	Disease	MESH:D007249
34118929	2097	2100	ALS	Disease	MESH:D000690
34118929	Negative_Correlation	MESH:D009534	11475
34118929	Association	MESH:D000690	203228
34118929	Negative_Correlation	MESH:D009534	MESH:D007249
34118929	Association	MESH:D000690	6275
34118929	Negative_Correlation	MESH:D009534	20198
34118929	Negative_Correlation	MESH:D009534	MESH:D000690
34118929	Negative_Correlation	MESH:D009534	6275
34118929	Negative_Correlation	MESH:D009534	MESH:D009133
34118929	Positive_Correlation	MESH:D007249	6275
34118929	Negative_Correlation	MESH:D009534	MESH:D005355
34118929	Negative_Correlation	MESH:D009534	MESH:D001480
34118929	Negative_Correlation	MESH:D009534	MESH:D005911
34118929	Negative_Correlation	MESH:D009534	18596

